- The cost of transporting a single vaccine is around Rs. 600: Expert
- There is a lack of investment in vaccine cold chains in India, say expert
- India has no facility of handling vaccines at extreme temperatures: Expert
Mumbai: Despite having one of the largest universal immunization programmes (UIPs), lack of cold chain may prove to be one of the biggest challenges for India in COVID-19 vaccine distribution, a foreign brokerage said on Wednesday (December 9). The cold chain market with 37 million tonne capacity is very fragmented in India, and the country does not have a single cold chain operator with a capacity of over 5,000 tonne, analysts at Bofa Securities said adding very few of the 3,500 companies are ‘pharma-compliant’ as per WHO norms.
India’s struggle with cold chain for COVID-19 vaccine stems from the fact that despite one of the large cold chain capacities in the world, there are not many large participants, they said.
It can be noted that India runs the widely successful polio immunization programme, where the vaccine is transported in temperatures ranging from 2-8 degrees Celsius and there is a dedicated cold chain, which is likely to be repurposed for the COVID-19 vaccine. However, the brokerage said the quantum of work is 16 times more than the 600 million doses under the UIP.
The brokerage estimated the cost of transporting a single vaccine at around Rs 600 and assuming that up to 400 million Indians are to be vaccinated, the overall logistics market comes at Rs 21,000 crore. However, the biggest stumbling block for investment activity is the uncertainty over which of the vaccine candidates get approved.
For overall 400 million doses forecast, India may need 30,000 tonne of transportation capacity which is about 11,500 vehicles, it said, adding as of 2018, India had 12,800 such vehicles. Pfizer’s and Moderna’s mRNA vaccines need extreme cold temperatures for stability whereas the one from AstraZeneca (AZN)/Oxford can be stored, transported and handled at standard refrigerated conditions between 2-8 degrees Celsius, it said, adding India does not have any facilities at all for transporting vaccines at ultra-low temperatures like -80 degrees Celsius required for the Pfizer vaccine.
There is also less visibility on future use of capacity which makes private players question return on investment (ROI) on such exercise, the analysts said, adding many private companies are waiting for clear directives from government and pharma companies. Manufacturing is likely to be concentrated in Ahmedabad (Cadila), Pune (Serum), Hyderabad (Bharat Biotech, Biological E, Dr Reddy’s) and Telangana (Aurobindo), it said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.